A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Astellas Pharma Inc
Therapeutic Advances in Childhood Leukemia Consortium
Masonic Cancer Center, University of Minnesota
Center for International Blood and Marrow Transplant Research
Memorial Sloan Kettering Cancer Center
Medical College of Wisconsin
Children's Oncology Group
Arog Pharmaceuticals, Inc.
Children's Oncology Group
Arog Pharmaceuticals, Inc.
University of Nebraska
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Eastern Cooperative Oncology Group
University of Washington
M.D. Anderson Cancer Center
Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
National Cancer Institute (NCI)
Goethe University
Goethe University
M.D. Anderson Cancer Center
Virginia Commonwealth University
St. Jude Children's Research Hospital
M.D. Anderson Cancer Center
Goethe University
Goethe University
Children's Oncology Group
University of Washington
University of Washington
H. Lee Moffitt Cancer Center and Research Institute
Stanford University
M.D. Anderson Cancer Center
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Dartmouth-Hitchcock Medical Center
Pfizer
M.D. Anderson Cancer Center
Array BioPharma
Masonic Cancer Center, University of Minnesota
PETHEMA Foundation
M.D. Anderson Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Fred Hutchinson Cancer Center
Washington University School of Medicine